HIV Infections Clinical Trial
— SANU GUNDOOfficial title:
Sanu Gundo (jòli sègèsègèli - furakèli - jàntoli): Survey on the Feasibility of the Community-based HIV Care, and Its Impact on Access and Retention in Care in Artisanal Gold Mining Zones in Mali
Sanu Gundo ANRS 12392 is a non-randomized and non-comparative intervention trial in Mali. The main objective of the project is to study the feasibility of the community-based HIV care in the context of the artisanal gold mining zones and to evaluate its contribution to the linkage-to-care of PLWHIV with the health system and their retention in care, as well as its effect on their health status.
Status | Recruiting |
Enrollment | 265 |
Est. completion date | December 28, 2022 |
Est. primary completion date | March 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - To live and/or to work in the sites of Kofoulatiè or Diassa (Mali) - To be diagnosed positive to HIV by ARCAD Santé PLUS (screening and enrolment tests positive) - To be 18 years or older - To speak one of the most common languages (Bambara, French or English) and to be able of providing informed consent In addition, to be included in the intervention group, people living with HIV in the Kofoulatiè site must accept the community-based HIV care provided by ARCAD Santé PLUS Exclusion Criteria: - Women pregnant at the time of the HIV screening test by ARCAD Santé PLUS, or needing ultrasound to confirm pregnancy - People with discordant screening and enrolment tests - People inebriated or under the influence of drugs at enrolment - Adults not able to understand and/or to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Mali | ARCAD Santé PLUS mobile care unit for recruitment of participants (Diassa, control site) | Diassa | Sikasso |
Mali | ARCAD Santé PLUS mobile care unit for community-based HIV care and study follow-up (Kofoulatiè, intervention site) | Kofoulaté | Koulikoro |
Mali | ARCAD Santé PLUS mobile care unit for recruitment of participants (Kofoulatiè, Intervention site) | Kofoulaté | Koulikoro |
Mali | Referral health center (CSRéf) Kolondieba, classic HIV care | Kolondieba | Sikasso |
Lead Sponsor | Collaborator |
---|---|
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | ARCAD Santé PLUS, SEREFO, UMR 1252 SESSTIM |
Mali,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Material and human resources available for healthcare supply around gold-mining zones | Description of the healthcare supply geographical distribution around the artisanal gold-mining zones included in the study;
Description of the available human and material resources in the healthcare centers around the artisanal gold-mining zones included in the study |
From enrolment (M0) to 12 months after HIV diagnosis (M12) | |
Other | Working conditions of healthcare professionals involved in the classic HIV care | Description of the socioeconomic and demographic characteristics of healthcare professionals in HIV care centers around the artisanal gold-mining zones included in the study;
Number of working hours, number of medical visits, earnings, perceived health status, etc. |
From enrolment (M0) to 12 months after HIV diagnosis (M12) | |
Primary | Lost to follow-up rate 12 months after the HIV diagnosis | It was defined on the basis of existing data: 1) lost to follow-up rate in HIV care at the national level in Mali (32% in 2019); 2) lost to follow-up rate in the HIV care of ARCAD Santé PLUS in urban areas (12% in 2019).
The primary endpoint is : the lost to follow-up rate in the community-based HIV care 12 months after diagnosis is (at least) 20 percentage points lower than the lost to follow-up rate in the classic HIV care. |
12 months after HIV diagnosis (M12) | |
Secondary | Extent of the HIV epidemic in the artisanal gold-mining sites | This outcome provides the prevalence of the HIV epidemic among people living/working in the artisanal gold-mining sites:
number of HIV positive tests as percentage of the total number of people living/working in the sites |
At enrolment (M0) | |
Secondary | Comparing linkage-to-care and retention between classic and community-based HIV care | For linkage-to-care:
Percentage of people living with HIV starting a treatment 1 month and 3 months after diagnosis Percentage of people living with HIV with available blood tests (CD4 count, Viral load, etc) at the beginning of ARV treatment For retention in care: % of people living with HIV present for HIV care visits at 3, 6, 9 and 12 months after diagnosis |
1 month after HIV diagnosis (M1) and 12 months after HIV diagnosis (M12) | |
Secondary | Comparing the impact of classic and community-based HIV care on virological succes, behavioral and psychosocial outcomes | CD4 count and viral load at the time of diagnosis (M0) and its evolution 6 and 12 months later (M6 and M12)
Self-perception of health status, sexual behavior indicators at M1 and evolution at M12: number of partners, number of sexual intercourses, etc. |
From enrolment (M0) to 12 months after HIV diagnosis (M12) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |